Verastem (VSTM) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

VSTM Stock Forecast

Verastem stock forecast is as follows: an average price target of $8.33 (represents a 111.96% upside from VSTM’s last price of $3.93) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

VSTM Price Target

The average price target for Verastem (VSTM) is $8.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $5.00. This represents a potential 111.96% upside from VSTM's last price of $3.93.

VSTM Analyst Ratings

Buy

According to 5 Wall Street analysts, Verastem's rating consensus is 'Buy'. The analyst rating breakdown for VSTM stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Verastem Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jul 29, 2024	Graig Suvannavejh	Mizuho Securities	-	-	152.71%	78.12%
May 24, 2024	Justin Zelin	BTIG	-	-	215.53%	230.79%
Apr 15, 2022	Gregory Renza	RBC Capital	-	-	182.49%	27.23%

Row per page

Go to

The latest Verastem stock forecast, released on Jul 29, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $7.00, which represents a 152.71% increase from the stock price at the time of the forecast ($2.77), and a 78.12% increase from VSTM last price ($3.93).

Verastem Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$10.00
Last Closing Price	$3.93	$3.93	$3.93
Upside/Downside	-100.00%	-100.00%	154.45%

In the current month, the average price target of Verastem stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verastem's last price of $3.93. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 30, 2024	Guggenheim		Buy	Initialise
May 28, 2024	RBC Capital	Outperform	Outperform	Hold
Jun 15, 2023	Mizuho Securities	Positive	Buy	Upgrade
Jun 15, 2023	Citigroup		Buy	Upgrade
Jun 15, 2023	Mizuho Securities		Positive	Upgrade
Apr 26, 2022	Zacks Investment Research		Hold	Upgrade
Apr 14, 2022	RBC Capital		Outperform	Initialise

Row per page

Go to

Verastem's last stock rating was published by Guggenheim on Sep 30, 2024. The company Initialise its VSTM rating from "null" to "Buy".

Verastem Financial Forecast

Verastem Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	$2.60M	$2.00K	$500.00K	$1.01M	$506.00K	$78.65M	$4.31M	$5.06M	$3.62M	$9.03M	$3.14M	$1.67M
Avg Forecast	$4.97M	$2.05M	$520.00K	$160.00K	$171.43K	$57.14K	$66.67K	$7.12M	$33.33K	$16.67K	$16.67K	$1.50M	$37.50K	$50.00K	$1.01M	$3.19M	$26.60M	$4.04M	$3.96M	$4.49M	$7.72M	$2.33M	$2.52M
High Forecast	$4.97M	$2.05M	$520.00K	$160.00K	$171.43K	$57.14K	$66.83K	$7.12M	$33.50K	$16.67K	$16.67K	$1.50M	$37.50K	$50.00K	$1.21M	$3.19M	$26.60M	$4.04M	$3.96M	$4.49M	$7.72M	$2.33M	$2.52M
Low Forecast	$4.97M	$2.05M	$520.00K	$160.00K	$171.43K	$57.14K	$66.50K	$7.12M	$33.17K	$16.67K	$16.67K	$1.50M	$37.50K	$50.00K	$804.80K	$3.19M	$26.60M	$4.04M	$3.96M	$4.49M	$7.72M	$2.33M	$2.52M
# Analysts	3	3	3	5	9	4	2	4	2	2	2	8	8	8	16	13	8	8	9	12	7	7	8
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.73%	0.05%	10.00%	1.00%	0.16%	2.96%	1.07%	1.28%	0.80%	1.17%	1.35%	0.66%

Verastem's average Quarter revenue forecast for Mar 23 based on 2 analysts is $16.67K, with a low forecast of $16.67K, and a high forecast of $16.67K. VSTM's average Quarter revenue forecast represents a -99.36% decrease compared to the company's last Quarter revenue of $2.60M (Mar 22).

Verastem EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	9	4	2	4	2	2	2	8	8	8	16	13	8	8	9	12	7	7	8
EBITDA	-	-	-	-	-	-	-	-	$-18.88M	$-20.29M	$-14.95M	$-16.91M	$-14.81M	$-15.86M	$-14.01M	$-19.38M	$15.28M	$-20.68M	$-26.81M	$-32.81M	$-24.56M	$-36.45M	$-32.61M
Avg Forecast	$-2.56M	$-1.05M	$-267.23K	$-82.22K	$-88.10K	$-29.37K	$-34.26K	$-3.66M	$-17.13K	$-8.56K	$-8.56K	$-14.77K	$-19.03K	$-25.38K	$-14.01M	$-1.62M	$-13.50M	$-2.05M	$-12.07M	$-2.28M	$-3.92M	$-1.18M	$-28.36M
High Forecast	$-2.56M	$-1.05M	$-267.23K	$-82.22K	$-88.10K	$-29.37K	$-34.17K	$-3.66M	$-17.04K	$-8.56K	$-8.56K	$-11.81K	$-19.03K	$-25.38K	$-11.21M	$-1.62M	$-13.50M	$-2.05M	$-9.65M	$-2.28M	$-3.92M	$-1.18M	$-22.69M
Low Forecast	$-2.56M	$-1.05M	$-267.23K	$-82.22K	$-88.10K	$-29.37K	$-34.35K	$-3.66M	$-17.21K	$-8.56K	$-8.56K	$-17.72K	$-19.03K	$-25.38K	$-16.81M	$-1.62M	$-13.50M	$-2.05M	$-14.48M	$-2.28M	$-3.92M	$-1.18M	$-34.03M
Surprise %	-	-	-	-	-	-	-	-	1101.87%	2369.18%	1744.89%	1144.93%	778.27%	625.00%	1.00%	11.96%	-1.13%	10.08%	2.22%	14.39%	6.27%	30.86%	1.15%

13 analysts predict VSTM's average Quarter EBITDA for Dec 20 to be $-1.62M, with a high of $-1.62M and a low of $-1.62M. This is -110.61% lower than Verastem's previous annual EBITDA (Sep 20) of $15.28M.

Verastem Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	9	4	2	4	2	2	2	8	8	8	16	13	8	8	9	12	7	7	8
Net Income	-	-	-	-	-	-	-	-	$-20.00M	$-24.28M	$-12.85M	$-16.97M	$-22.79M	$-16.90M	$-15.03M	$-19.86M	$13.14M	$-23.01M	$-37.99M	$-38.77M	$-30.14M	$-42.19M	$-38.10M
Avg Forecast	$-27.68M	$-27.78M	$-31.00M	$-33.62M	$-31.63M	$-29.70M	$-38.75M	$-24.61M	$-33.93M	$-42.00M	$-40.26M	$-14.84K	$-27.24M	$-26.86M	$-15.03M	$-27.40M	$13.97M	$-47.28M	$-17.10M	$-146.66M	$-147.47M	$-161.81M	$-33.13M
High Forecast	$-27.68M	$-27.78M	$-31.00M	$-33.62M	$-29.03M	$-29.70M	$-38.75M	$-23.71M	$-33.93M	$-42.00M	$-40.26M	$-11.87K	$-27.24M	$-26.86M	$-12.02M	$-27.40M	$13.97M	$-47.28M	$-13.68M	$-146.66M	$-147.47M	$-161.81M	$-26.51M
Low Forecast	$-27.68M	$-27.78M	$-31.00M	$-33.62M	$-32.92M	$-29.70M	$-38.75M	$-25.22M	$-33.93M	$-42.00M	$-40.26M	$-17.81K	$-27.24M	$-26.86M	$-18.04M	$-27.40M	$13.97M	$-47.28M	$-20.51M	$-146.66M	$-147.47M	$-161.81M	$-39.76M
Surprise %	-	-	-	-	-	-	-	-	0.59%	0.58%	0.32%	1143.39%	0.84%	0.63%	1.00%	0.73%	0.94%	0.49%	2.22%	0.26%	0.20%	0.26%	1.15%

Verastem's average Quarter net income forecast for Dec 20 is $-27.40M, with a range of $-27.40M to $-27.40M. VSTM's average Quarter net income forecast represents a -308.54% decrease compared to the company's last Quarter net income of $13.14M (Sep 20).

Verastem SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	9	4	2	4	2	2	2	8	8	8	16	13	8	8	9	12	7	7	8
SG&A	-	-	-	-	-	-	-	-	$7.36M	$7.40M	$7.33M	$5.93M	$5.52M	$6.71M	$6.22M	$40.84M	$20.61M	$15.44M	$19.60M	$23.73M	$22.15M	$29.30M	$26.43M
Avg Forecast	$28.73M	$11.85M	$3.00M	$923.96K	$989.96K	$329.99K	$384.99K	$41.12M	$192.49K	$96.25K	$96.25K	$5.19K	$216.55K	$288.74K	$5.81M	$18.43M	$153.61M	$23.34M	$22.85M	$25.95M	$44.58M	$13.44M	$14.54M
High Forecast	$28.73M	$11.85M	$3.00M	$923.96K	$989.96K	$329.99K	$385.94K	$41.12M	$193.45K	$96.25K	$96.25K	$6.23K	$216.55K	$288.74K	$6.97M	$18.43M	$153.61M	$23.34M	$22.85M	$25.95M	$44.58M	$13.44M	$14.54M
Low Forecast	$28.73M	$11.85M	$3.00M	$923.96K	$989.96K	$329.99K	$384.02K	$41.12M	$191.53K	$96.25K	$96.25K	$4.15K	$216.55K	$288.74K	$4.65M	$18.43M	$153.61M	$23.34M	$22.85M	$25.95M	$44.58M	$13.44M	$14.54M
Surprise %	-	-	-	-	-	-	-	-	38.25%	76.87%	76.15%	1143.13%	25.50%	23.25%	1.07%	2.22%	0.13%	0.66%	0.86%	0.91%	0.50%	2.18%	1.82%

Verastem's average Quarter SG&A projection for Dec 23 is $41.12M, based on 4 Wall Street analysts, with a range of $41.12M to $41.12M. The forecast indicates a 458.42% rise compared to VSTM last annual SG&A of $7.36M (Sep 23).

Verastem EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Dec 23	Sep 23	Jun 23	Mar 23	Mar 22	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	3	3	3	5	9	4	2	4	2	2	2	8	8	8	16	13	8	8	9	12	7	7	8
EPS	-	-	-	-	-	-	-	-	$-0.75	$-1.37	$-0.06	$-0.09	$-0.13	$-0.10	$-0.09	$-0.12	$0.08	$-0.14	$-0.35	$-0.36	$-0.41	$-0.57	$-0.52
Avg Forecast	$-0.69	$-0.69	$-0.77	$-0.83	$-0.79	$-0.74	$-0.96	$-0.61	$-0.84	$-1.04	$-1.00	$-0.98	$-1.01	$-1.00	$-1.08	$-1.02	$0.52	$-1.76	$-2.67	$-5.46	$-5.49	$-6.02	$-5.48
High Forecast	$-0.69	$-0.69	$-0.77	$-0.83	$-0.72	$-0.74	$-0.96	$-0.59	$-0.84	$-1.04	$-1.00	$-0.98	$-1.01	$-1.00	$-1.08	$-1.02	$0.52	$-1.76	$-2.67	$-5.46	$-5.49	$-6.02	$-5.48
Low Forecast	$-0.69	$-0.69	$-0.77	$-0.83	$-0.82	$-0.74	$-0.96	$-0.63	$-0.84	$-1.04	$-1.00	$-0.98	$-1.01	$-1.00	$-1.08	$-1.02	$0.52	$-1.76	$-2.67	$-5.46	$-5.49	$-6.02	$-5.48
Surprise %	-	-	-	-	-	-	-	-	0.89%	1.31%	0.06%	0.09%	0.13%	0.10%	0.08%	0.11%	0.15%	0.08%	0.13%	0.07%	0.07%	0.09%	0.09%

According to 13 Wall Street analysts, Verastem's projected average Quarter EPS for Dec 20 is $-1.02, with a low estimate of $-1.02 and a high estimate of $-1.02. This represents a -1375.00% decrease compared to VSTM previous annual EPS of $0.08 (Sep 20).

Verastem Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INFI	Infinity Pharmaceuticals	-	-	29900.00%	Buy
KPTI	Karyopharm Therapeutics	-	-	839.74%	Buy
VSTM	Verastem	-	-	111.96%	Buy
TRVN	Trevena	-	-	104.68%
VKTX	Viking Therapeutics	-	-	98.33%	Buy

VSTM Forecast FAQ

Is Verastem a good buy?

Yes, according to 5 Wall Street analysts, Verastem (VSTM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of VSTM's total ratings.

What is VSTM's price target?

Verastem (VSTM) average price target is $8.33 with a range of $5 to $13, implying a 111.96% from its last price of $3.93. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Verastem stock go up soon?

According to Wall Street analysts' prediction for VSTM stock, the company can go up by 111.96% (from the last price of $3.93 to the average price target of $8.33), up by 230.79% based on the highest stock price target, and up by 27.23% based on the lowest stock price target.

Can Verastem stock reach $6?

VSTM's average twelve months analyst stock price target of $8.33 supports the claim that Verastem can reach $6 in the near future.

What are Verastem's analysts' financial forecasts?

Verastem's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $295.24K (high $295.4K, low $295.07K), average EBITDA is $-152K (high $-152K, low $-152K), average net income is $-100M (high $-97.475M, low $-101M), average SG&A $1.7M (high $1.71M, low $1.7M), and average EPS is $-2.486 (high $-2.421, low $-2.518). VSTM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $7.71M (high $7.71M, low $7.71M), average EBITDA is $-3.96M (high $-3.96M, low $-3.96M), average net income is $-120M (high $-120M, low $-120M), average SG&A $44.5M (high $44.5M, low $44.5M), and average EPS is $-2.982 (high $-2.982, low $-2.982).

Did the VSTM's actual financial results beat the analysts' financial forecasts?

Based on Verastem's last annual report (Dec 2020), the company's revenue was $88.52M, beating the average analysts forecast of $37.79M by 134.23%. Apple's EBITDA was $-47.59M, beating the average prediction of $-29.238M by 62.77%. The company's net income was $-67.726M, missing the average estimation of $-77.801M by -12.95%. Apple's SG&A was $62.76M, missing the average forecast of $218.23M by -71.24%. Lastly, the company's EPS was $-5.3, beating the average prediction of $-4.93 by 7.51%. In terms of the last quarterly report (Mar 2022), Verastem's revenue was $2.6M, beating the average analysts' forecast of $1.5M by 73.07%. The company's EBITDA was $-16.906M, beating the average prediction of $-14.766K by 114392.75%. Verastem's net income was $-16.969M, beating the average estimation of $-14.841K by 114238.66%. The company's SG&A was $5.93M, beating the average forecast of $5.19K by 114213.23%. Lastly, the company's EPS was $-0.0911, missing the average prediction of $-0.984 by -90.74%